The short version of analytical characterisation fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-07. Anything still debated is marked as such rather than presented as settled.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
William de la Founte, a wealthy Bristol merchant has been identified as the first recorded English slave traders. Of Gascon origin, in 1480 he was one of the four venturers granted a licence "to trade in any parts". Renewed growth came with the 17th-century rise of England's American colonies and the rapid 18th-century expansion of Bristol's part in the "Triangular trade" in Africans taken for slavery in the Americas. Over 2000 slaving voyages were made by Bristol ships between the late 17th century and abolition in 1807, carrying an estimated half a million people from Africa to the Americas in brutal conditions. Average profits per voyage were seventy per cent and more than fifteen per cent of the Africans transported died or were murdered on the Middle Passage. Some slaves were brought to Bristol, from the Caribbean; notable among these were Scipio Africanus, buried at Henbury and Pero Jones brought to Bristol by slave trader and plantation owner John Pinney. The slave trade and the consequent demand for cheap brass ware for export to Africa caused a boom in the copper and brass manufacturing industries of the Avon valley, which in turn encouraged the progress of the Industrial Revolution in the area. Prominent manufacturers such as Abraham Darby and William Champion developed extensive works between Conham and Keynsham which used ores from the Mendips and coal from the North Somerset coalfield. Water power from tributaries of the Avon drove the hammers in the brass batteries, until the development of steam power in the later 18th century.
The normal range for fasting blood sugar in people without diabetes is 70 to 99 mg/dL (3.9 to 5.5 mmol/L). The range for individuals considered to have prediabetes is 100 to 125 mg/dL (5.6 to 6.9 mmol/L). If the fasting blood sugar is greater than 126 mg/dL (7.0 mmol/L) on blood tests taken on separate occasions, individuals are considered to have diabetes. Another useful test that is usually done via a blood test is the measurement of blood HbA1c (hemoglobin A1c) levels. In the blood, there is a molecule called hemoglobin which carries oxygen to the cells. Glucose can attach itself to this molecule and if the blood glucose is consistently high, the value of the A1c will increase. This test, unlike the other tests, is measured as a percentage because the test measures the proportion of all the hemoglobin that has glucose attached. This test measures the average amount of blood sugar control over a period of about 3 months (90 days). In people without diabetes, the HbA1c level ranges from 4.0 to 5.7%. The range for people with prediabetes is 5.7 to 6.4%, and anything above 6.4% is considered diabetic range. Due to the HbA1c serving as an accurate indicator of overall glycemic control, regular 6 month laboratory testing of HbA1c (glycated hemoglobin) is recommended to gauge long-term control and allows for more information to then adjust a person's lifestyle as well as routine medication dosages in such cases. Optimal management of diabetes involves individuals measuring and recording their own blood glucose levels.
Metallic zinc was isolated in India by 1300 AD. Before it was isolated in Europe, it was imported from India in about AD 1600. Postlewayt's Universal Dictionary, a contemporary source giving technological information in Europe, did not mention zinc before 1751 but the element was studied before then. Flemish metallurgist and alchemist P. M. de Respour reported that he had extracted metallic zinc from zinc oxide in 1668. By the start of the 18th century, Étienne François Geoffroy described how zinc oxide condenses as yellow crystals on bars of iron placed above zinc ore that is being smelted. In Britain, John Lane is said to have carried out experiments to smelt zinc, probably at Landore, prior to his bankruptcy in 1726. In 1738 in Great Britain, William Champion patented a process to extract zinc from calamine in a vertical retort-style smelter. His technique resembled that used at Zawar zinc mines in Rajasthan, but no evidence suggests he visited the Orient. Champion's process was used through 1851. German chemist Andreas Marggraf normally gets credit for isolating pure metallic zinc in the West, even though Swedish chemist Anton von Swab had distilled zinc from calamine four years previously. In his 1746 experiment, Marggraf heated a mixture of calamine and charcoal in a closed vessel without copper to obtain a metal. This procedure became commercially practical by 1752.
Sources: en.wikipedia.org
leveling effect The effect of a solvent on the chemical properties of acids or bases which are dissolved in the solvent. The strength of a strong acid is limited or "leveled" by the basicity of the solvent, and likewise the strength of a strong base is limited by the acidity of the solvent, such that the effective pH of the solution is higher or lower than might be suggested by the acid's or base's dissociation constant.
== Photochemical conversion == Photochemical conversion occurs due to interactions between the chromophoric unit and residues in its vicinity. Glu-212 functions as a base that removes a proton from His-62 aiding in the cleavage of the His-62-Nα-Cα bond. Replacing Glu-212 with glutamine prevents photoconversion. At low pH, the yield of Eos involved in photoconversion is greatly increased as the fraction of molecules in the protonated form increases. The action spectrum for photoconversion is closely related to the action spectrum for Eos's protonated form. These observations suggest that the neutral form of the green chromophore, including a protonated Tyr-63 side chain, is the gateway structure for photoconversion. Proton ejection from the Tyr-63 phenyl side chain is an important event in the conversion mechanism where a proton is transferred from the His-62 imidazole, which is hydrogen-bonded to the Phe-61 carbonyl. The extra proton causes His-62 to donate a proton to the Phe-61 carbonyl forming a leaving group out of the peptide bond between His and Phe in the elimination reaction. The His-62 side chain is protonated during photoexcitation and assists the reaction by donating a proton to the Phe-61 carbonyl in the leaving group. After the backbone is cleaved, the hydrogen bond between His-62 and Phe-61 is reformed. When His-62 is replaced with other amino acids, EosFP loses its ability to photoconvert, providing evidence that His-62 is a necessary component of the photoconversion mechanism.
== History == The first benchtop detector was introduced in 2014 with detection capabilities between 120 and 240 nm. This portion of the ultraviolet spectrum had historically been restricted to bright source synchrotron facilities due to significant background absorption challenges inherent to working within the wavelength range. Further detector platform development has extended the wavelength detection range out from 120 to 430 nm.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.